Stefano Malvolti is Managing Director and Co-Founder of MMGH. He has over 16 years of experience in global health and pharmaceutical industry in program management, strategy, policy, finance and supply chain. Currently he is also Member of the Board of Directors of the Fondazione Achile Sclavo in Siena, Italy, an NGO focused on facilitating vaccine development for neglected diseases.
During 2016, he served as Chief Executive Officer at Univac in Brussels, an early stage Biotech company developing a new vaccine platform for viral diseases. Under his tenure, the company redefined its governance mechanisms, its strategy and defined its preclinical development plan. Previously he was for 3,5 years the Director of Vaccine Implementation at Gavi, the Vaccine Alliance where was responsible for the coordination of the roll-out of Gavi’s 11 vaccine programs with more than 150 country launches. He also led the GAVI Alliance Coverage and Equity initiative aimed at defining a new approaches and country strategies to steer the Alliance towards its 2020 goal of number of children vaccinated. Mr. Malvolti chaired the GAVI Alliance’s Vaccine Implementation Management Team. He was also a member of WHO’s Global Polio Eradication Initiative’s Immunization Management Group and Ebola Vaccine Deployment Steering Group.
Prior to Gavi, he was Global Policy Director at Novartis Vaccines, responsible for the business unit’s relations with the WHO, UNICEF and GAVI and for the negotiation of the Pandemic Influenza Preparedness framework. In the starting years of his career he was Director of Strategic Vaccines Supply at PATH where he implemented state-of-the art processes that raised GAVI’s forecasts reliability and was member of UNICEF Supply Division procurement reference groups for Pneumococcal and Rotavirus vaccines. Before he served in various positions in Novartis Pharma and Baxter Healthcare in strategic forecasting, outsourcing, sales and operations planning and finance.
Stefano holds a Master in Public Health from Johns Hopkins Bloomberg School of Public Health in Baltimore and a Master in Business Economics from Bocconi University in Milan
Carsten Mantel is Managing Director and Co-Founder of MMGH. Dr. Mantel has more than 30 years of work experience in the field of prevention and control of communicable diseases with focus on vaccines and immunizations. He has worked as a primary care physician in Europe and in the African Region, where he was also instrumental in establishing district primary health care, community health services and disease control interventions for HIV/AIDS and malaria.
Dr. Mantel lives in Berlin, Germany, where he holds a part-time position as Senior Advisor Immunization in the Infectious Disease Epidemiology Department of the Robert Koch Institute, the major German Public Health Institute. Prior to this, he worked at the Institute of Tropical Medicine of the Charité Medical School of Humboldt University in Berlin as Head of the International Health Programme. He performed epidemiological studies in the field of communicable and non-communicable diseases, and assisted countries in the development of comprehensive disease control strategic plans and their implementation.
Dr. Mantel was the Leader of the Priority Area on New Vaccines and Innovation in WHO’s Department of Immunization, Vaccines and Biologicals / Expanded Programme on Immunization for almost 10 years. In this position he was – among other things – responsible for policy and strategy development and assistance to countries for the introduction of new and underused vaccines and for supporting integrated approaches to vaccine-preventable disease prevention and control.
He qualified in Medicine from the Ludwig-Maximilians University in Munich, Germany, where he also obtained his doctorate degree. In addition, he holds a Master of Public Health degree with a focus on epidemiological methods from the Harvard School of Public Health.
Thomas Cherian is a medical doctor with over 30 years experience in infectious diseases, epidemiology and immunization. He served for 17 years at the World Health Organization. He served as the Coordinator for the Expanded Programme on Immunization in the Department of Immunization, Vaccines and Biologicals at WHO, Geneva at the time of his retirement. Prior to this he was the Coordinator for Implementation Research in the Initiative for Vaccine Research at WHO in Geneva. He also holds the position of Senior Associate in the Department of International Health at the Johns Hopkins Bloomberg School of Public Health, Baltimore, USA.
Before joining WHO, Dr Cherian was Professor of Paediatrics at the Christian Medical College in Vellore, India, where he did his medical training as well as his post graduate training in Paediatrics. Subsequently, he did a three-year fellowship in Paediatric Infectious Diseases at the Johns Hopkins University School of Medicine, Baltimore.
Dr Cherian has authored or co-authored over 130 scientific articles and book chapters. His main research interests have been related to acute respiratory infections in children. His research has contributed to the case management protocols for acute respiratory infections in children and for policy development for the use of Pneumococcal and Hib vaccines worldwide. He has played an important role in the roll out of new vaccines in low- and middle -income countries, from policy development, supporting country decision-making processes, and implementation planning to establishing sentinel site surveillance networks to document the impact of these vaccines.
Melissa Ko has over 14 years of experience in global health and consulting with experience in program design and management, strategy, policy, and analytics. Prior to joining MMGH, Mrs. Ko was part of Gavi, the Vaccine Alliance’s Vaccine Implementation team with a range of responsibilities across Gavi’s pneumococcal, rotavirus, cholera, and typhoid programmes. These programmes accounted for over 40% of Gavi’s 9.3 billion budget during 2016-20. Further, she led efforts to ensure efficiencies in Gavi’s programmes as well as designing Gavi’s new investments and programmes, which resulted revised and expanded support for the cholera programme and the Board approval for typhoid conjugate vaccines with financial commitments of US$85m from 2019-20. She also participated in key policy reviews such as the 2013 and 2018 Vaccine Investment Strategy and Gavi’s comprehensive stockpile review. Mrs. Ko also chaired Gavi’s Vaccine Implementation vaccine sub-teams for her responsible programmes.
Prior to joining Gavi’s Vaccine Implementation team, Mrs. Ko’s work primarily focused on analytics, including responsibility for Gavi’s Strategic Demand Forecasts from a Market Shaping perspective as well as providing monitoring and evaluation activities and developing of costing tools related HIV / AIDS interventions. She was also a manager at Deloitte for over 5 years where she served as an economist providing technical advice to a wide variety of industries, including pharmaceuticals, consumer products, energy, and real estate.
Mrs. Ko holds a Master of Science in Public Health in International Health from Johns Hopkins Bloomberg School of Public Health in Baltimore and Bachelor of Arts in Economics and Sociology from Emory University in Atlanta.
Melissa Malhame, MBA– led Gavi’s market shaping efforts until late 2017. In that capacity Ms. Malhame was accountable for ensuring adequate and timely supply of vaccines at affordable prices for Gavi, for setting long-term access strategies for sixteen vaccines, for forecasting long-term demand and working closely with UNICEF Supply Division. She has served on numerous Procurement Reference Groups and currently is a member of the Center for Global Development working group on the Future of Global Healthcare Procurement. Prior to her role at Gavi, Ms. Malhame had a twenty-year career in the vaccine industry spanning commercial, policy, regulatory and strategy roles.
Sam Sternin has worked across sub-Saharan Africa, South and Southeast Asia, spanning numerous fields in health and beyond. Within public health, his experience includes work on immunization, maternal & adolescent health, child nutrition, and HIV/AIDS. He has a strong focus on behavior change, urban health, and service delivery to marginalized populations, with an emphasis on bridging the divide between strategy and ground-level implementation. Functionally, Sam has worked on capacity development, strategy, institutional reform and program design, delivery, and M&E. Over the course of his career, he’s worked for local and international NGOs, UN agencies, private foundations, and developing country governments. He has degrees from Harvard (Social Studies) and Princeton (Public Affairs with a certification in Health Policy), and is a native speaker of English, French, and Vietnamese, with fluency in Spanish and Amharic.